Depo-Medrol

Depo-Medrol Indications/Uses

methylprednisolone

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma

Marketer:

DKSH
Full Prescribing Info
Indications/Uses
Glucocorticoids should only be considered as symptomatic treatment, unless in case of some endocrine disorders, where they are used as a substitution treatment.
FOR INTRAMUSCULAR ADMINISTRATION: Methylprednisolone acetate (DEPO-MEDROL) is not suitable for the treatment of acute life threatening conditions. If a rapid hormonal effect of maximum intensity is required, the I.V. administration of highly soluble methylprednisolone sodium succinate (SOLU-MEDROL) is indicated. When oral therapy is not feasible and this preparation lend to the treatment of the condition, the intramuscular use of DEPO-MEDROL is indicated as follows:
ANTI-INFLAMMATORY TREATMENT: Rheumatic disorders: As adjuvant of a maintenance therapy (analgetics, kinesitherapy, fysiotherapy, etc.) and for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; ankylosing spondylitis.
For the following indications, preference should be given to in situ administration if possible: post-traumatic osteoarthritis; synovitis of osteoarthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); acute and subacute bursitis; epicondylitis; acute nonspecific tenosynovitis; acute gouty arthritis.
Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus; systemic dermatomyositis (polymyositis); acute rheumatic carditis.
Dermatologic diseases: pemphigus; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; mycosis fungoides; bullous dermatitis herpetiformis (sulfone is the drug of first choice and systemic administration of glucocorticoids is an adjuvant).
Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: chronic asthmatic respiratory disorders; contact dermatitis; atopic dermatitis; serum sickness; seasonal or perennial allergic rhinitis; drug hypersensitivity reactions; urticarial transfusion reactions; acute noninfectious laryngeal edema (epinephrine is the drug of first choice).
Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: herpes zoster ophthalmicus; iritis, iridocyclitis; chorioretinitis; diffuse posterior uveitis; optic neuritis.
Gastrointestinal diseases: To tide the patient over a critical period of the disease in: ulcerative colitis (systemic therapy); Crohn disease (systemic therapy).
Edematous states: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
Respiratory diseases: symptomatic pulmonary sarcoidosis; berylliosis; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; Loeffler's syndrome not manageable by other means; aspiration pneumonitis.
TREATMENT OF HEMATOLOGICAL AND ONCOLOGICAL DISORDERS: Hematologic disorders: acquired (autoimmune) hemolytic anemia; secondary thrombocytopenia in adults; erythroblastopenia (RSC anemia); congenital (erythroid) hypoplastic anemia.
Oncological diseases: For palliative management of: leukemias and lymphomas; acute leukemia of childhood.
ENDOCRINE DISORDERS: primary or secondary adrenocortical insufficiency; acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice. Synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance.); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis.
MISCELLANEOUS: tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy; trichinosis with neurologic or myocardial involvement; nervous system: acute exacerbations of multiple sclerosis.
FOR INTRASYNOVIAL, PERIARTICULAR, INTRABURSAL OR SOFT TISSUE ADMINISTRATION (see PRECAUTIONS).
DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; acute gouty arthritis; synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; acute gouty arthritis; epicondylitis; acute nonspecific tenosynovitis; post-traumatic osteoarthritis.
FOR INTRALESIONAL ADMINISTRATION: DEPO-MEDROL is indicated for intralesional use in the following conditions: keloids; localized hypertropic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus (neurodermatitis); discoid lupus erythematosus; alopecia areata.
DEPO-MEDROL may also be useful in cystic tumors or an aponeurosis or tendon (ganglia).
FOR INTRARECTAL INSTILLATION: Ulcerative colitis.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in